Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease

(2020) Jakob Appel Østergaard et al.   JOURNAL OF NEPHROLOGY

Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis

(2020) Arpeeta Sharma et al.   DIABETES

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

(2019) Rebecca C. Coll et al.   Nature Chemical Biology

The role of inflammasomes in kidney disease

(2019) Takanori Komada et al.   Nature Reviews Nephrology

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation

(2019) CongXiao Zhang et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

(2018) Paul M Ridker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evidence against a role for NLRP3-driven islet inflammation in db/db mice

(2018) H.L. Kammoun et al.   Molecular Metabolism

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension

(2018) Shalini M Krishnan et al.   CARDIOVASCULAR RESEARCH

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetes and Kidney Disease: Role of Oxidative Stress

(2016) Jay C. Jha et al.   ANTIOXIDANTS & REDOX SIGNALING

The NLRP3 inflammasome in kidney disease and autoimmunity

(2016) Holly L Hutton et al.   NEPHROLOGY

Role of the nucleotide-binding domain-like receptor protein 3 inflammasome in acute kidney injury

(2015) Yanhui Cao et al.   FEBS Journal

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy

(2015) Khurrum Shahzad et al.   KIDNEY INTERNATIONAL

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

(2015) Rebecca C Coll et al.   NATURE MEDICINE

Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy

(2014) Pan Gao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy

(2014) J. C. Jha et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Thrombomodulin domain 1 ameliorates diabetic nephropathy in mice via anti-NF-κB/NLRP3 inflammasome-mediated inflammation, enhancement of NRF2 antioxidant activity and inhibition of apoptosis

(2013) Shun-Min Yang et al.   DIABETOLOGIA

Quercetin and Allopurinol Ameliorate Kidney Injury in STZ-Treated Rats with Regulation of Renal NLRP3 Inflammasome Activation and Lipid Accumulation

(2012) Chuang Wang et al.   PLoS One

LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile

(2012) Tarak Srivastava et al.   Journal of Cell Communication and Signaling

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice

(2009) A. M. D. Watson et al.   DIABETOLOGIA